Fundraising Fox
Fortress Biotech
NASDAQ: FBIONew York, US · Delaware corporation · 1 known investors
Find your way into Fortress Biotech
Sign up to see every warm intro you have to Fortress Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Fortress Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fortress Biotech is a biopharmaceutical company that acquires and advances assets across therapeutic areas including oncology, dermatology, and rare diseases, generating value through product revenue, equity holdings, and dividend and royalty income. The company operates a portfolio of marketed prescription pharmaceutical products and development programs through majority-owned subsidiaries and minority ownership positions in partner companies.
Founders & leadership
LA
Lindsay A. RosenwaldChief Executive OfficerLindsay Rosenwald is a physician and executive with over 30 years in life sciences, who has worked in venture capital, direct investing, and investment banking. He graduated from Pennsylvania State University with a bachelor's degree in finance and economics and holds a medical degree; throughout his career, he has led the development of multiple clinical-stage medicines, several of which received FDA approval across oncology, psychiatry, and other therapeutic areas.
MS
Michael S. WeissExecutive
GA
George AvgerinosExecutive
LL
Lucy LuChief Strategy OfficerLucy Lu has held CFO, COO, and CEO positions at private and public biotechnology companies across multiple therapeutic areas, and previously worked as a senior equity research analyst covering small- to mid-cap biotech firms. She brings expertise in biotech asset evaluation, clinical development, regulatory strategy, business development, and capital markets.
Board
EK
Eric K. RowinskyBoard director
DK
Dov KleinBoard director
JH
Jimmie Harvey, Jr.Board director
MH
Malcolm HoenleinBoard director
JJ
J. Jay LobellBoard director
Investors · 1
Frazier Life SciencesreportedPalo Alto
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.8M disclosed across 2 of 6 rounds · 1900–2026
▶$6.5MraisedMar 2018 · 2 investors · BiotechnologyRule 506(b)
▶$6.5MraisedMar 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J. Jay LobellDirector
- George AvgerinosExecutive Officer
- Dov KleinDirector
- Malcolm HoenleinDirector
- Jimmie Harvey, Jr.Director
- Eric K. RowinskyDirector
- Michael WeissExecutive Officer, Director
- Robyn HunterExecutive Officer
- Lindsay A. RosenwaldExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $6.5M
- Sales commissions
- $521.4K
- Placement agents
- National Securities Corporation
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedApr 2017 · 2 investors · BiotechnologyRule 506(b)
▶$3.3MraisedApr 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric K. RowinskyDirector
- Lindsay A. RosenwaldExecutive Officer, Director
- Michael S. WeissDirector
- Dov KleinDirector
- Jimmie Harvey, Jr.Director
- Malcolm HoenleinDirector
- J. Jay LobellDirector
- George AvgerinosExecutive Officer
- Lucy LuExecutive Officer
- Amount sold
- $3.3M
- Sales commissions
- $325.4K
- Placement agents
- National Securities Corporation
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$118.1Mvaluation at IPOJun 2012 · $5.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Companies working in the same space as Fortress Biotech.
In the news
Frequently asked questions
- What does Fortress Biotech do?
- Fortress Biotech is a biopharmaceutical company that acquires and advances assets across therapeutic areas including oncology, dermatology, and rare diseases, generating value through product revenue, equity holdings, and dividend and royalty income. The company operates a portfolio of marketed prescription pharmaceutical products and development programs through majority-owned subsidiaries and minority ownership positions in partner companies.
- Who are Fortress Biotech's investors?
- Fortress Biotech's investors include Frazier Life Sciences.
- How much funding has Fortress Biotech raised?
- Fortress Biotech has disclosed $9.8M raised across 2 of its 6 known rounds.
- Where is Fortress Biotech headquartered?
- Fortress Biotech is headquartered in New York, US.